Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E5555 is an investigational drug (not described in the provided sources; based on external knowledge it is a selective protease-activated receptor-1 [PAR-1] antagonist developed for cardiovascular indications). Diltiazem is a non-dihydropyridine calcium channel blocker used to treat hypertension (high blood pressure), angina (chest pain), and certain heart arrhythmias. It works by inhibiting the influx of calcium ions into cardiac and vascular smooth muscle cells during depolarization. This action relaxes blood vessels and reduces the workload on the heart while increasing coronary blood flow. Diltiazem is approved for use as an antihypertensive agent and antianginal agent[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on E5555 + diltiazem.